***Background.*** This phase 4, randomized, placebo-controlled, double-blind, study evaluated immune responses after coadministration of 13-valent pneumococcal conjugate vaccine (PCV13) and a quadrivalent inactivated influenza vaccine (QIV) in adults aged ≥50 years previously immunized with 23-valent pneumococcal polysaccharide (PPSV23).

***Methods.*** Subjects received PCV13 + QIV then placebo 1 month later (group 1) or placebo + QIV then PCV13 1 month later (group 2). Opsonophagocytic activity (OPA) geometric mean titers (GMTs) and hemagglunation inhibition assay (HAI) GMTs for 13 pneumococcal serotypes and 4 influenza strains, respectively, were assessed before and 1 month after vaccination. The prespecified noninferiority criterion was 2-fold (0.5 lower limit of 95% CI for GMT ratios). Adverse events (AEs) and serious AEs (SAEs) were assessed.

***Results.*** The evaluable immunogenicity population in groups 1 and 2 comprised 421 and 425 subjects, respectively (mean age, years \[±SD\], 67.0 \[±9.08\] and 66.4 \[±8.84\]); \>93% of subjects had received ≥1 PPSV23 dose. The noninferiority criterion was met for OPA GMTs for all 13 pneumococcal serotypes (table 1). In most cases, GMT point estimates were lower when PCV13 was coadministered, with significantly lower GMTs (upper limit of the 95% CI \<1 on the GMT ratio) for serotypes 3, 4, 6A, and 14. Baseline HAI GMTs were similar between groups and rose postvaccination. Noninferiority was met for all 4 QIV strains (table 2). Seroconversion rates (4-fold rise in pre- versus postvaccination HAI titer) were low but similar between groups (range, 21.3%--31.6%). A post hoc analysis showed similarpercentages of subjects achieving HAI titers ≥1:40 in groups 1 and 2, respectively, (90.6% and 89.3% for A/H1N1, 98.4% and 96.5% for A/H3N2, 49.2% and 46.5% for B/Brisbane, and 65.8% and 63.3% for B/Massachusetts). Responses for B strains were low in both groups. SAEs reported were consistent with conditions expected in this population; none were vaccine-related.
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***Conclusion.*** Immune responses to PCV13 and QIV were non-inferior to PCV13 given alone, but associated with lower PCV13 responses that were significantly lower for 4 serotypes. Concomitant PCV13 and QIV administration yielded similar HAI responses compared to QIV alone, and was well tolerated.
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